Physician profile
Heather Koza
NPI 1194045526
$2,870.01
in general payments reported to CMS, 2019-2025
26 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.33 · 2020: $25.53 · 2021: $217 · 2022: $451 · 2023: $462 · 2024: $939 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $877.67 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $684.04 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $324.33 | 2021-2024 | |
| Exact Sciences Corporation | $139.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $120.83 | 2024 | Breztri |
| Alkermes, INC. | $119.96 | 2024-2025 | Lybalvi, Aristada |
| Cranial Technologies, INC | $75.87 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $66.49 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.40 | 2021-2025 | Xifaxan |
| Alk-Abello, INC | $56.89 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Abbott Laboratories | $46.20 | 2024-2025 | Id Now Instrument, Freestyle Libre 3 |
| Pfizer INC. | $44.60 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $27.53 | 2023-2025 | Contrave, Onzetra Xsail |
| Mayne Pharma Commercial LLC | $25.97 | 2023 | |
| Boston Scientific Corporation | $25.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.87 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $17.63 | 2023 | Acuvue |
| Glaxosmithkline, LLC. | $17.40 | 2019 | |
| Verrica Pharmaceuticals INC. | $15.66 | 2025 | Ycanth |
| Teva Pharmaceuticals USA, INC. | $15.20 | 2019 | |
| Neos Therapeutics, LP | $15.03 | 2024 | Cotempla Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $14.09 | 2025 | Rexulti |
| Gilead Sciences, INC. | $14.00 | 2025 | |
| Acella Pharmaceuticals, LLC | $13.66 | 2024 | NP Thyroid 60 |
| Seqirus USA INC | $13.54 | 2022 | |
| Allergan, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Koza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.